CA3266872A1 - Co-crystals of derivatives of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxyethoxy]pyrazolo[1,5-A]pyridin-6-yl]-5-methyltriazol-1-yl]piperidine-1-carbonitrile with gallic acid and nicotine amide - Google Patents

Co-crystals of derivatives of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxyethoxy]pyrazolo[1,5-A]pyridin-6-yl]-5-methyltriazol-1-yl]piperidine-1-carbonitrile with gallic acid and nicotine amide

Info

Publication number
CA3266872A1
CA3266872A1 CA3266872A CA3266872A CA3266872A1 CA 3266872 A1 CA3266872 A1 CA 3266872A1 CA 3266872 A CA3266872 A CA 3266872A CA 3266872 A CA3266872 A CA 3266872A CA 3266872 A1 CA3266872 A1 CA 3266872A1
Authority
CA
Canada
Prior art keywords
pyrazolo
triazol
pyridin
piperidine
pyridyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3266872A
Other languages
English (en)
French (fr)
Inventor
David Andrew Coates
Lori Raquel HILDEN
Gislaine Kuminek
Jeffrey A. Peterson
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA3266872A1 publication Critical patent/CA3266872A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3266872A 2022-09-07 2023-09-06 Co-crystals of derivatives of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxyethoxy]pyrazolo[1,5-A]pyridin-6-yl]-5-methyltriazol-1-yl]piperidine-1-carbonitrile with gallic acid and nicotine amide Pending CA3266872A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263404232P 2022-09-07 2022-09-07
US63/404,232 2022-09-07
PCT/US2023/073508 WO2024054814A1 (en) 2022-09-07 2023-09-06 Co-crystals of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxy-ethoxy]pyrazolo[1,5-a]pyridin-6-yl]-5-methyl- triazol-1-yl]piperidine-1 -carbonitrile derivatives with gallic acid and nicotine amide

Publications (1)

Publication Number Publication Date
CA3266872A1 true CA3266872A1 (en) 2024-03-14

Family

ID=88204177

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3266872A Pending CA3266872A1 (en) 2022-09-07 2023-09-06 Co-crystals of derivatives of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxyethoxy]pyrazolo[1,5-A]pyridin-6-yl]-5-methyltriazol-1-yl]piperidine-1-carbonitrile with gallic acid and nicotine amide

Country Status (16)

Country Link
US (1) US20240116932A1 (enExample)
EP (1) EP4584270A1 (enExample)
JP (2) JP7541606B2 (enExample)
KR (1) KR20250057022A (enExample)
CN (1) CN120187720A (enExample)
AR (1) AR130417A1 (enExample)
AU (1) AU2023338199A1 (enExample)
CA (1) CA3266872A1 (enExample)
CL (1) CL2025000596A1 (enExample)
CO (1) CO2025002467A2 (enExample)
CR (1) CR20250077A (enExample)
DO (1) DOP2025000054A (enExample)
IL (1) IL319342A (enExample)
PE (1) PE20251400A1 (enExample)
TW (1) TWI862146B (enExample)
WO (1) WO2024054814A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025259519A1 (en) 2024-06-13 2025-12-18 Eli Lilly And Company Activation of egfr/her2/3 in cancer after treatment with an inhibitor of fibroblast growth factor receptor 3 (fgfr3)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067727A2 (en) 2005-12-08 2007-06-14 Ssci, Inc. Metronidazole cocrystals and imipramine cocrystals
PH12012000132A1 (en) 2011-06-09 2014-10-20 Servier Lab New co-crystals of agomelatine, a process for their preparation and pharmaceutical compositions containing them
CN102964384B (zh) 2012-11-09 2015-06-24 中山大学 阿德福韦酯没食子酸共晶及其制备方法和组合物
JP2021523876A (ja) 2018-02-13 2021-09-09 トランスジェネックス ナノバイオテック、インコーポレイテッド 癌治療のためのタミバロテンの新規の結晶形態
US12180207B2 (en) * 2018-12-19 2024-12-31 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of FGFR tyrosine kinases
CN111574359A (zh) 2019-02-19 2020-08-25 愈磐生物科技（苏州）有限公司 乐伐替尼-没食子酸共晶晶型及其应用
CN113943284B (zh) 2020-07-15 2023-12-19 中国医学科学院药物研究所 盐酸吡格列酮没食子酸共晶及制备方法和其组合物与用途
TW202402754A (zh) 2021-03-04 2024-01-16 美商美國禮來大藥廠 Fgfr3抑制劑化合物

Also Published As

Publication number Publication date
DOP2025000054A (es) 2025-03-31
CR20250077A (es) 2025-04-02
TW202428260A (zh) 2024-07-16
TWI862146B (zh) 2024-11-11
CN120187720A (zh) 2025-06-20
CL2025000596A1 (es) 2025-04-25
CO2025002467A2 (es) 2025-03-17
PE20251400A1 (es) 2025-05-22
JP2024037713A (ja) 2024-03-19
JP2024153948A (ja) 2024-10-29
JP7541606B2 (ja) 2024-08-28
WO2024054814A1 (en) 2024-03-14
AR130417A1 (es) 2024-12-04
KR20250057022A (ko) 2025-04-28
US20240116932A1 (en) 2024-04-11
IL319342A (en) 2025-05-01
AU2023338199A1 (en) 2025-03-20
EP4584270A1 (en) 2025-07-16

Similar Documents

Publication Publication Date Title
EP2400961B1 (de) Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
EP0793498B1 (en) Bicyclic heterocyclic compounds for the treatment of impotence
EP0702555B1 (en) Pyrazolopyrimidinones for the treatment of impotence
CA2676786C (en) Imidazoquinolines as dual lipid kinase and mtor inhibitors
EP2400962B1 (de) Arzneimittelkombinationen enthaltend pde4-inhibitoren und nsaids
KR100363714B1 (ko) 니트레이트-유발된 내성을 치료하기 위한 약학 조성물
WO2001012171A3 (en) Pharmaceutical compositions comprising clavulanic acid or derivative thereof for the treatment of behavioral diseases
US8877758B2 (en) Combinations of medicaments, containing PDE4-inhibitors and EP4-receptor-antagonists
WO2004085409A3 (en) Compounds and libraries of pyridines, pyrazines, imidazo[1,2-a]pyrazines and 1h-imidazo[4,5-b]pyrazin-2-ones and first and second medical uses thereof
CA3266872A1 (en) Co-crystals of derivatives of 4-[4-[3-chloro-4-[1-(2-pyridyl)-2-hydroxyethoxy]pyrazolo[1,5-A]pyridin-6-yl]-5-methyltriazol-1-yl]piperidine-1-carbonitrile with gallic acid and nicotine amide
MX2023005626A (es) Derivados de pirazolo[1.5-a]pirazina como inhibidores de la btk.
EP1145714A1 (en) Drugs
CA3266687A1 (en) PYRAZOLO[1,5-A]PYRIDINE AND IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS FGFR3 INHIBITORS FOR CANCER TREATMENT
JP2007526285A (ja) Ｐｄｅ５阻害剤のための新規の使用
US20040058914A1 (en) Combination drugs
NO20063768L (no) 1H-tieno[2,3c] pyrazolderivater anvendelige som kinaseinhibitorer
US5436253A (en) Pyridonecarboxylic acid derivatives and mycotic infections
EP4286386A4 (en) Salt form and crystal form of a pyrazole-substituted imidazo[1,2-a]quinoxaline derivative
WO2004085436A3 (en) Pyrido[2,3-d]pyrimidin-7-carboxylic acid derivatives, their manufacture and use as pharmaceutical agents
WO2000035428A2 (de) Tricyclische stickstoffheterocyclen als pde iv inhibitoren
JP5707338B2 (ja) ラセミのアミノプテリンを含む医薬組成物
JP2002249432A (ja) 併用剤
EP3133072B1 (en) Novel 6,7-dihydro-3h-oxazolo[3,4-a]pyrazine-5,8-dione derivative compounds
HK40088917A (en) Crystalline forms of 3-cyano-1-[4-[6-(1-methyl-1h-pyrazol-4-yl)pyrazolo[1,5-a]pyrazin-4-yl]-1h-pyrazol-1-yl]cyclobutaneacetonitrile, and use thereof
CA3262884A1 (en) Pharmaceutically acceptable salt and polymorph of substituted pyrazolo[1,5-a]pyrimidin-7-amine derivative and use thereof